| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 4.606 | 15.862 | 572.479 | 106.362 | 6.833 | 0 |
| Total Income - EUR | - | - | - | - | 4.606 | 15.862 | 572.479 | 106.512 | 6.833 | 2 |
| Total Expenses - EUR | - | - | - | - | 26.735 | 14.468 | 437.770 | 144.838 | 13.551 | 8.929 |
| Gross Profit/Loss - EUR | - | - | - | - | -22.130 | 1.394 | 134.709 | -38.326 | -6.718 | -8.927 |
| Net Profit/Loss - EUR | - | - | - | - | -22.176 | 591 | 128.721 | -39.391 | -6.718 | -8.927 |
| Employees | - | - | - | - | 2 | 1 | 1 | 1 | 0 | 0 |
Check the financial reports for the company - Vivax Pharmaceuticals Roumania S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 416 | 409 | 3.077 | 2.724 | 2.355 | 1.983 |
| Current Assets | - | - | - | - | 3.833 | 9.447 | 144.595 | 20.443 | 13.779 | 7.954 |
| Inventories | - | - | - | - | 0 | 2.855 | 2.655 | 3.031 | 492 | 489 |
| Receivables | - | - | - | - | 1.445 | 4.752 | 113.469 | 12.683 | 8.443 | 4.884 |
| Cash | - | - | - | - | 2.388 | 1.840 | 28.471 | 4.730 | 4.844 | 2.581 |
| Shareholders Funds | - | - | - | - | -22.134 | -21.124 | 108.066 | -11.761 | -18.443 | -27.267 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 26.383 | 30.980 | 39.606 | 34.928 | 34.577 | 37.204 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Vivax Pharmaceuticals Roumania S.r.l.